Hims & Hers’ ugly split with Wegovy maker weighs on the telehealth company’s future

Telehealth firm Hims & Hers experienced a significant stock decline following a public fallout with Novo Nordisk, which terminated their partnership over Hims & Hers' alleged "deceptive" marketing and sales of unapproved compounded versions of Wegovy. Hims & Hers countered, accusing Novo Nordisk of anti-competitive practices. This dispute highlights escalating tensions between telehealth platforms and pharmaceutical companies regarding drug distribution and the use of compounded medications, potentially impacting Hims & Hers' projected revenue from its weight loss offerings despite its broader growth and diversification efforts.

Analysis

The public termination of the partnership between Hims & Hers (HIMS) and Novo Nordisk (NVO) has exposed significant operational and legal risks for the telehealth company, triggering a severe negative market reaction that erased nearly a third of its valuation. The core of the dispute centers on HIMS's sale of compounded, or 'knock-off', versions of the popular weight-loss drug Wegovy, which NVO alleges involves 'deceptive' marketing and risks patient safety. This conflict highlights a fundamental challenge to HIMS's disruptive business model, which relies on providing lower-cost alternatives that test regulatory boundaries, particularly as the FDA has issued warnings about non-medically necessary compounded drugs. While HIMS has demonstrated robust top-line growth, reaching $1.48 billion in revenue in 2024 and achieving profitability, the loss of the NVO partnership creates a significant revenue gap, casting doubt on its projection that weight loss offerings would contribute over $725 million in 2025. The event, underscored by a strongly negative sentiment score (-0.8 for HIMS), reframes the company as a direct competitor to pharmaceutical giants rather than a distribution partner, a position reinforced by NVO's new collaborations with LifeMD and WeightWatchers.

Key Decisions for Investors

• Investors should closely monitor for any regulatory actions from the FDA or legal challenges from Novo Nordisk, as the legality of HIMS's compounded drug sales is the central risk to its business model.
• Scrutinize upcoming earnings reports for evidence of the company's ability to offset the lost Novo Nordisk revenue, specifically assessing the growth rates of its non-weight loss business segments.
• Given the stock's high volatility and recent sharp decline, investors should be prepared for further price swings contingent on news flow related to the ongoing dispute and its regulatory fallout.
• Re-evaluate HIMS's competitive standing against platforms like LifeMD and WeightWatchers, which now have formal partnerships with Novo Nordisk for branded Wegovy distribution, potentially eroding HIMS's market share.